Verzenio (abemaciclib) receives positive reimbursement recommendation from CADTH for early breast cancer

1 November 2022 - Lilly Canada announced today that CADTH has issued their final reimbursement recommendation for Verzenio (abemaciclib) in ...

Read more →

A perspective on life cycle health technology assessment and real world evidence for precision oncology in Canada

25 October 2022 - Health technology assessment can be used to make healthcare systems more equitable and efficient. Advances in precision ...

Read more →

Trying to survive: To access lifesaving drugs, young cancer patients face huge hurdles

10 October 2022 - Four years ago, Ontarian Rebecca Grundy got a nightmare diagnosis that sent her into a blind ...

Read more →

Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer

5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...

Read more →

Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion

7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba

24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...

Read more →

AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...

Read more →

Patient access to affordable cancer treatment increases with the launch of new biosimilar in Canada

9 November 2021 - Apobiologix today launched its first oncology therapeutic treatment Bambevi (bevacizumab), which is used in combination with ...

Read more →

AbbVie receives a positive reimbursement recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

26 August 2021 - pERC recommends reimbursement of Venclexta (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute ...

Read more →

Roche Canada announces collaboration to improve access to personalised health care with real world evidence

28 May 2021 - BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate ...

Read more →

'I would be able to live into my thirties:' Nova Scotia woman has high hopes for new cancer treatment

21 May 2021 - Maria Stevens was diagnosed with cervical cancer two years ago. Now, with a new treatment on ...

Read more →

Coverage of oncology medicines well aligned across Canadian provinces, but sources of funding differ

4 May 2021 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, today ...

Read more →

GSK’s Zejula is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy

4 May 2021 - Zejula (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology ...

Read more →

CCRM and Amgen partner to advance emerging medical innovations

29 April 2021 - New fund to support regenerative medicine discoveries with high potential impact for patients. ...

Read more →